Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
Eli Lilly is testing EloraTZP, a combination of the experimental drug eloralintide and tirzepatide, to increase weight loss in adults with type 2 diabetes. In a 48-week trial, the highest dose produced an average weight loss of 23.3 percent, outperforming tirzepatide alone, which yielded 14.8 percent. However, the combination therapy saw a high dropout rate, with up to 27 percent of participants stopping treatment due to adverse events. This approach aims to enhance the efficacy of existing GLP-1 medications by adding amylin-targeting properties.
Listen to Live Briefing
Real-time synthesized voice briefing ยท Live Feeds Desk
- โ EloraTZP produced an average weight loss of 23.3 percent over 48 weeks at the highest tested dose for adults with obesity or overweight and type 2 diabetes.
- โ Tirzepatide alone resulted in a 14.8 percent average weight loss in the same trial group.
- โ Up to 27 percent of combination treatment recipients discontinued the trial because of adverse events.
- โ The FDA approved tirzepatide as Zepbound for adults with a BMI of 30 or more, or 27 or more with a weight-related health condition.
What changed
The current update identifies eloralintide as the specific experimental drug being paired with tirzepatide to form EloraTZP.
Live updates
-
Lilly tests eloralintide and tirzepatide combination for weight loss
Eli Lilly is testing EloraTZP, a combination of the experimental drug eloralintide and tirzepatide, to increase weight loss in adults with type 2 diabetes. In a 48-week trial, the highest dose produced an average weight loss of 23.3 percent, outperforming tirzepatide alone, which yielded 14.8 percent. However, the combination therapy saw a high dropout rate, with up to 27 percent of participants stopping treatment due to adverse events. This approach aims to enhance the efficacy of existing GLP-1 medications by adding amylin-targeting properties.
Why it matters
Tirzepatide is already FDA-approved for obesity as Zepbound and for type 2 diabetes as Mounjaro. It competes directly with Novo Nordisk's Wegovy in the chronic weight management market. The development of triple-action therapies represents an effort to push weight loss percentages higher than current dual-agonist drugs.
What is confirmed
- EloraTZP produced an average weight loss of 23.3 percent over 48 weeks at the highest tested dose for adults with obesity or overweight and type 2 diabetes.
- Tirzepatide alone resulted in a 14.8 percent average weight loss in the same trial group.
- Up to 27 percent of combination treatment recipients discontinued the trial because of adverse events.
- The FDA approved tirzepatide as Zepbound for adults with a BMI of 30 or more, or 27 or more with a weight-related health condition.
- Tirzepatide is marketed as Mounjaro for the treatment of type 2 diabetes.
What to watch next
- Clinical trial results for eloralintide in non-diabetic obesity patients
- FDA regulatory filing for the EloraTZP combination therapy
confidence 95%Sources used for this update (3)
- madamenoire.com โ Eli Lilly's New Weight-Loss Drug Shows Eye-Popping Results
- pharmaphorum.com โ Lilly gets FDA okay for tirzepatide as obesity therapy
- pspeptides.com โ EloraTZP: Eloralintide + Tirzepatide Trial Data (2026)
-
Eli Lilly's EloraTZP Triple-Action Drug Hits 23 Percent Weight Loss
Eli Lilly's experimental triple-action combination treatment, EloraTZP, produced a 23.3 percent average weight loss over 48 weeks in adults with obesity or overweight and type 2 diabetes at the highest tested dose, compared with 14.8 percent for tirzepatide alone. However, the trial revealed a high dropout rate, with up to 27 percent of combination recipients discontinuing treatment because of adverse events. The findings highlight the push by drugmakers to utilize amylin-targeting drugs to complement existing GLP-1 medications and achieve greater weight loss.
Why it matters
Eli Lilly and rival Novo Nordisk are actively developing amylin-targeting treatments to power a new wave of obesity medications following GLP-1 therapies. As of October 3, 2026, Lilly maintains a market lead with second-quarter revenue rising 48 percent to $22.97 billion and a market value of about $1.02 trillion. Meanwhile, the intensifying market showdown has spilled over into US courts with lawsuits over advertising.
What is confirmed
- Eli Lilly reported Phase 2b results for EloraTZP showing a 23.3 percent average weight loss over 48 weeks at the highest dose in a trial of 367 adults.
- Up to 27 percent of combination recipients in the EloraTZP trial discontinued treatment because of adverse events.
- Eli Lilly's second-quarter revenue rose 48 percent to $22.97 billion and its market value sits at about $1.02 trillion.
Still unconfirmed
- Novo Nordisk faces an expected FDA decision on CagriSema in the fourth quarter of 2026.
What to watch next
- The upcoming FDA decision on Novo Nordisk's CagriSema in the fourth quarter of 2026
- Eli Lilly's planned filing for retatrutide in the first quarter of 2027
confidence 95%Sources used for this update (8)
- www.onedayadvisor.com โ Eli Lilly vs. Novo Nordisk โ The GLPโ1 Market Showdown (2026 ...
- www.diabetes.co.uk โ New triple-action treatment produces 23% weight loss in ...
- rocketnews.com โ Why Lilly and Novo are betting on amylin to power a new wave ...
- www.trialsitenews.com โ Lilly's Triple-Action Diabetes Treatment Delivers 23% Weight ...
- www.biospace.com โ Weight loss - BioSpace
- pharmaphorum.com โ Novo sues Lilly over 'misleading' GLP-1 ad campaigning
- finance.yahoo.com โ Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's ...
- economictimes.indiatimes.com โ zepbound: Latest News & Videos, Photos about zepbound | The ...
-
Lilly's amylin-Zepbound combo shows 20% weight loss in mid-stage trials
Eli Lilly's experimental combination drug, pairing eloralintide with Zepbound, achieved an average weight loss of 20 percent in mid-stage trials for type 2 diabetes and obesity patients. The treatment's progress comes as Lilly faces developments with its existing obesity and diabetes therapies, including a price increase for Mounjaro in the UK and a setback with Zepbound's coverage.
Why it matters
The pharmaceutical firm is advancing its pipeline with the amylin-targeting drug eloralintide, which has shown promise in addressing obesity and type 2 diabetes. Lilly's recent market performance and decisions on its existing therapies, such as the UK price increase for Mounjaro and the dropped coverage for Zepbound, contribute to the evolving landscape of its weight-loss and diabetes treatments.
What is confirmed
- Eli Lilly's experimental combination drug achieved an average weight loss of 20 percent in mid-stage trials.
- Gastrointestinal side effects led to treatment discontinuations of up to 27 percent in a previous study.
- Eli Lilly increased the UK price of Mounjaro by up to 170%.
- CVS Health will no longer cover Lilly's weight-loss therapy Zepbound.
Still unconfirmed
- Lilly is preparing to push its experimental combination drug EloraTZP into phase 3 testing during the fourth quarter.
What to watch next
- Lilly's phase 3 testing of EloraTZP
- Further updates on Zepbound's coverage and Mounjaro's pricing
- Results from additional trials of eloralintide
confidence 85%Sources used for this update (4)
- pharmaphorum.com โ Lilly reports 20% weight loss with amylin-targeting drug
- finance.yahoo.com โ This Drug Combination for Eli Lilly Generated Significantly ...
- londondaily.com โ Eli Lilly to Increase UK Price of Mounjaro by Up to 170%
- pharmaphorum.com โ Lilly hit as PBM drops Zepbound, but retains Wegovy
-
Eli Lilly Reaches Trillion-Dollar Valuation as Phase 3 Tests Approach
Eli Lilly advanced to a $1 trillion market capitalization in November 2025, becoming the first health-care company worldwide to achieve this milestone. The pharmaceutical firm is currently preparing to push its experimental combination drug EloraTZP into phase 3 testing during the fourth quarter. Mid-stage trials for the treatment, which pairs the amylin asset eloralintide with the obesity drug Zepbound for type 2 diabetes and obesity patients, showed an average weight loss of 23.3 percent at the highest dose. However, gastrointestinal side effects led to treatment discontinuations reaching up to 27 percent in the study.
Why it matters
Headquartered in Indianapolis, Indiana, Eli Lilly markets products in approximately 90 countries and ranks as the most valuable pharmaceutical company worldwide. The advancement of the EloraTZP regimen builds upon its established portfolio in diabetes and obesity treatments. Managing high discontinuation rates from gastrointestinal side effects remains a key operational hurdle as the drug moves into late-stage testing.
What is confirmed
- Eli Lilly reached a $1 trillion market capitalization in November 2025, becoming the first health-care company in the world to do so.
- The experimental combination drug EloraTZP pairs the amylin asset eloralintide with the obesity drug Zepbound.
- Mid-stage trials showed an average weight loss of 23.3 percent at the highest dose compared to 14.8 percent for tirzepatide alone.
- Treatment discontinuations reached up to 27 percent due to gastrointestinal side effects during testing.
What to watch next
- Initiation of phase 3 testing for EloraTZP during the fourth quarter
- Results tracking gastrointestinal side effects and discontinuation rates in late-stage trials
confidence 100%Sources used for this update (2)
- careers.lilly.com โ Browse Jobs and Available Openings | Lilly Careers
- en.wikipedia.org โ Eli Lilly and Company - Wikipedia
-
Eli Lilly Advances EloraTZP Combo to Phase 3 Trials
Eli Lilly is advancing its experimental combination drug EloraTZP into phase 3 testing during the fourth quarter following successful mid-stage trials. The treatment pairs the amylin asset eloralintide with the obesity drug Zepbound to treat patients with type 2 diabetes and obesity. In study results, the regimen achieved an average weight loss of 23.3 percent at the highest dose compared to 14.8 percent for tirzepatide alone, while meeting primary and secondary endpoints. Treatment discontinuations reached up to 27 percent due to gastrointestinal side effects.
Why it matters
The mid-stage data underscores an ongoing industry shift toward next-generation metabolic combinations in chronic weight management. Eli Lilly CEO David Ricks stated from the company Indianapolis headquarters that the obesity drug revolution is only getting started as portfolio assets generate billions. Alongside the EloraTZP program, the company released phase 3 data for its triple-hormone agonist retatrutide, which reached 28.3 percent weight loss.
What is confirmed
- Eli Lilly reported mid-stage trial results for EloraTZP, combining eloralintide with Zepbound.
- The regimen achieved an average weight loss of 23.3 percent at the highest dose compared to 14.8 percent for tirzepatide alone in adults with obesity and type 2 diabetes.
- Treatment discontinuations reached up to 27 percent due to gastrointestinal side effects.
- Eli Lilly CEO David Ricks stated at the Indianapolis headquarters that the obesity drug revolution is only getting started.
Still unconfirmed
- Tirzepatide will be the best-selling drug of all time.
What to watch next
- Initiation and progress of EloraTZP phase 3 testing in the fourth quarter
- Further clinical data releases regarding retatrutide and combination assets
confidence 95%Sources used for this update (6)
- primexbt.com โ Eli Lilly's Weight Loss Combo EloraTZP Beats Tirzepatide in Phase 2 Trial
- health.yahoo.com โ Eli Lillyโs New Drug Combo Just Set A Record For Weight Loss ...
- www.advisory.com โ Around the nation: Eli Lilly's new obesity drug combo boosts ...
- worldattention.com โ Eli Lillyโs retatrutide and combo drugs show record weight ...
- www.matterfact.com โ Retatrutide Hits 28% Weight Loss and Lilly's Amylin Combo ...
- finance.biggo.com โ David Ricks: Tirzepatide Will Be the Best-Selling Drug of All ...
-
Lilly reports EloraTZP trial success and discontinuation rates
Eli Lilly reported mid-stage trial results for EloraTZP, combining the amylin asset eloralintide with the obesity drug Zepbound. In adults with obesity and type 2 diabetes, the regimen achieved an average weight loss of 23.3 percent at the highest dose, compared to 14.8 percent for tirzepatide alone, while meeting primary and secondary endpoints. However, treatment discontinuations reached up to 27 percent due to gastrointestinal side effects. The company also advanced its cardiovascular safety testing for Foundayo and navigated CMS finalizations for international pricing under Medicare Part B.
Why it matters
The Phase 2 trial results position Eli Lilly to launch a Phase 3 trial for the combination therapy before the end of the year. This development highlights ongoing industry efforts to push efficacy thresholds in obesity and diabetes management by pairing incretin treatments with amylin analogs.
What is confirmed
- At the highest dose, the combination produced average weight loss of 23.3%.
- Treatment discontinuations reached up to 27%.
Still unconfirmed
- Foundayo passed its cardiovascular safety test, and CMS finalized international pricing for Medicare Part B.
What to watch next
- Launch of the Phase 3 trial before the end of the year
- Further safety and discontinuation data from late-stage trials
confidence 100%Sources used for this update (2)
- theclinicaltimes.com โ Lillyโs amylin-Zepbound combination led to 23.3% weight loss ...
- updates.biomednexus.com โ Lilly Stacked an Amylin on Zepbound and Won
-
Eli Lilly Reports Strong Results for Amylin-Zepbound Obesity Combo
Eli Lilly reported mid-stage trial results for EloraTZP, a combination of the amylin asset eloralintide and the approved obesity drug Zepbound. In adults with obesity and type 2 diabetes, the regimen delivered a weight loss of 23.3 percent compared to 14.8 percent for tirzepatide alone. The therapy also achieved greater A1C reduction than tirzepatide 15 mg. The combination swept primary and secondary endpoints in the Phase 2 trial. However, the higher reduction in weight came with an increased rate of treatment discontinuation due to gastrointestinal side effects. Eli Lilly plans to launch a Phase 3 trial before the end of the year.
Why it matters
The new data follows other major developments in weight-loss medications, including trial results for Lilly's retatrutide GLP-1 and reports of patients losing up to 60 pounds on the company's treatments. The pharmaceutical company continues to advance advanced combination regimens targeting better blood sugar control and higher weight loss thresholds. These mid-stage results position the amylin-tirzepatide combination for advanced clinical testing as the company seeks to build upon the success of its existing portfolio.
What is confirmed
- Eli Lilly's EloraTZP combines eloralintide and tirzepatide.
- The Phase 2 trial of adults with obesity and type 2 diabetes showed 23.3 percent weight loss for the combination versus 14.8 percent for tirzepatide alone.
- EloraTZP delivered greater weight loss and A1C reduction compared to tirzepatide 15 mg.
- Eli Lilly intends to start a Phase 3 trial before the end of the year.
Still unconfirmed
- Gastrointestinal side effects led to a higher rate of patients stopping treatment during the trial.
What to watch next
- Launch of the Phase 3 clinical trial before the end of the year
- Further safety and discontinuation data from extended trials
confidence 100%Sources used for this update (12)
- The Guardian โ โGodzillaโ of weight-loss drugs could provide other important health benefits
- NBC News โ People with Type 2 diabetes lost up to 60 pounds on Lillyโs latest weight loss drug
- CNBC โ Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Eli Lilly โ Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
- USA Today โ Lilly's retatrutide GLP-1 delivers average weight loss of 50 pounds
- Fierce Biotech โ Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
- Yahoo โ EASD 2026: Lillyโs amylin-tirzepatide combo beats its weight loss drug alone
- www.medicaldaily.com โ Lilly's Eloralintide Plus Tirzepatide Produced 23.3% Weight Loss in Phase 2 Trial of Adults with Type 2 D....
- www.careyounews.org โ ์ฐจ์ธ๋ ๋น๋ง ์ ์ฝ์ ์ ญ๋ฐ์ด๋์ ๋ณ์ฉํ ์ค๊ธฐ ์์, ์ 2ํ ๋น๋จ๋ณ ํ์ ์ฒด์ค ํ๊ท 23.3ํผ์ผํธ ๊ฐ์
- www.biospace.com โ Superior weight loss, blood sugar control propel Lillyโs ...
- www.prnewswire.com โ Lilly's EloraTZP (combination of eloralintide and tirzepatide ...
- joeymed.com โ EloraTZP in 2026: Lilly's Amylin-Tirzepatide Combo Posts 23% ...
Community Sentiment: How do you assess this situation?
Voice your perspective ยท Real-time aggregated sentiment from the Live Feeds community